IXICO has announced its largest pharma client has halted dosing patients in its phase 3 and open-label Huntington's disease studies following a pre-planned review of the data. IXICO has indicated a maximum impact of c£2.7m on FY21E revenues, though we see this as a worst-case scenario as enrolled patients will continue to be monitored, at least in the near-term. We believe the total contracted revenue value to IXICO associated with this programme was £24.8m over the timeframe FY19A to FY24E and ....
24 Mar 2021
Cenkos: IXICO Plc -- Huntington's trial update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: IXICO Plc -- Huntington's trial update
IXICO Plc (IXI:LON) | 8.8 0 0.0% | Mkt Cap: 4.23m
- Published:
24 Mar 2021 -
Author:
Chris Donnellan -
Pages:
7
IXICO has announced its largest pharma client has halted dosing patients in its phase 3 and open-label Huntington's disease studies following a pre-planned review of the data. IXICO has indicated a maximum impact of c£2.7m on FY21E revenues, though we see this as a worst-case scenario as enrolled patients will continue to be monitored, at least in the near-term. We believe the total contracted revenue value to IXICO associated with this programme was £24.8m over the timeframe FY19A to FY24E and ....